Q2 2016 Holdings
Filed 2016-08-12 | 23 holdings | $16.6M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Coherus Biosciences Inc(CHRS) | COM | 19249H103 | $10.3M | 611,010 | 62.1% |
| BioCryst Pharmaceuticals Inc(BCRX) | COM | 09058V103 | $2.9M | 1,005,104 | 17.2% |
| BeiGene Ltd(ONC) | COM | 07725L102 | $1.5M | 51,000 | 9.1% |
| Ascendis Pharma A/S(ASND) | COM | 04351P101 | $1.2M | 90,000 | 7.2% |
| CytomX Therapeutics Inc(CTMX) | COM | 23284F105 | $656.0K | 64,200 | 3.9% |
| DBV Technologies | COM | F2927N109 | $29.1K | 456,893 | 0.2% |
| Heron Therapeutics Inc(HRTX) | COM | 427746102 | $19.8K | 1,095,734 | 0.1% |
| Flamel Technologies S.A. | COM | 338488109 | $5.4K | 500,000 | 0.0% |
| Zafgen Inc | COM | 98885E103 | $3.6K | 602,114 | 0.0% |
| Adverum Biotechnologies(ADVMCHF) | COM | 00773U108 | $3.5K | 1,102,735 | 0.0% |
| Alcobra Ltd | COM | M2239P109 | $2.8K | 623,313 | 0.0% |
| Lipocine Inc | COM | 53630X104 | $2.6K | 849,921 | 0.0% |
| Axovant Sciences Ltd | COM | G0750W104 | $2.4K | 184,110 | 0.0% |
| Akari Therapeutics Plc | COM | 00972G108 | $2.1K | 158,352 | 0.0% |
| Cynapsus Therapeutics Inc | COM | 23257Y701 | $1.8K | 108,575 | 0.0% |
| Ocera Therapeutics | COM | 67552A108 | $1.5K | 796,550 | 0.0% |
| Edge Therapeutics Inc | COM | 279870109 | $1.4K | 135,000 | 0.0% |
| Arca biopharma Inc | COM | 00211Y100 | $1.3K | 462,399 | 0.0% |
| Global Blood Therapeutics | COM | 37890U108 | $1.2K | 72,990 | 0.0% |
| Stemline Therapeutics Inc | COM | 85858C107 | $917 | 135,420 | 0.0% |
| Regenxbio Inc(RGNX) | COM | 75901B107 | $420 | 52,500 | 0.0% |
| ProNAI Therapeutics Inc | COM | 74346L101 | $112 | 56,056 | 0.0% |
| Aeglea BioTherapeutics(AGLEUSD) | COM | 00773J103 | $29 | 6,000 | 0.0% |